Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
IMMUNE CHECKPOINT INHIBITORS AVAILABLE IN PHARMACOTHERAPY AND THEIR IMMUNE RELATED ADVERSE EFFECTS
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HPS-107
- By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
- Co-author(s): Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
Andreia Gaspar: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
Olímpia Fonseca: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal - Abstract:
Background
The immune checkpoint inhibitors (ICPI) have revolutionized the treatment of various oncological pathologies. These drugs target the signaling pathways of the immune system, contributing to restore immune responses against cancer cells. However, stimulation of the immune system can lead to overactivation of T-lymphocytes, causing
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023